carvedilol has been researched along with Injury, Myocardial Reperfusion in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pretreatment with carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion." | 7.74 | Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. ( Cui, C; Gao, R; Yang, Y; you, S; Zhao, J, 2007) |
| "These results indicate that carvedilol has the inhibitory effect against reperfusion arrhythmias in rats and suggest that the mechanism of action of this compound is related to the combined effects of beta-blocking and antioxidant." | 7.70 | The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats. ( Ijiri, H; Ishihara, T; Kohno, I; Komori, S; Matsumura, K; Osada, M; Sawanobori, T; Takusagawa, M; Tamura, K; Umetani, K, 2000) |
| " The present experiment evaluated the effects of carvedilol, a new beta adrenoreceptor blocker with potent free radical-scavenging activity, on myocardial ischemia and reperfusion injury in a hypercholesterolemic rabbit model." | 7.69 | Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. ( Barone, FC; Christopher, TA; Feuerstein, GZ; Lopez, BL; Ma, XL; Ruffolo, RR; Yue, TL, 1996) |
| "Pretreatment with carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion." | 3.74 | Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion. ( Cui, C; Gao, R; Yang, Y; you, S; Zhao, J, 2007) |
| "Carvedilol, a selective alpha1 and non-selective beta-adrenoceptor antagonist and antioxidant, has been shown to provide significant cardiac protection in animal models of myocardial ischemia." | 3.70 | Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model. ( Arch, JR; Cheng, HY; Feuerstein, G; Hieble, JP; Liu, GL; Ma, XL; Ruffolo, RR; Yue, TL, 1998) |
| "These results indicate that carvedilol has the inhibitory effect against reperfusion arrhythmias in rats and suggest that the mechanism of action of this compound is related to the combined effects of beta-blocking and antioxidant." | 3.70 | The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats. ( Ijiri, H; Ishihara, T; Kohno, I; Komori, S; Matsumura, K; Osada, M; Sawanobori, T; Takusagawa, M; Tamura, K; Umetani, K, 2000) |
| " The present experiment evaluated the effects of carvedilol, a new beta adrenoreceptor blocker with potent free radical-scavenging activity, on myocardial ischemia and reperfusion injury in a hypercholesterolemic rabbit model." | 3.69 | Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits. ( Barone, FC; Christopher, TA; Feuerstein, GZ; Lopez, BL; Ma, XL; Ruffolo, RR; Yue, TL, 1996) |
| "Carvedilol treatment restored the IS reduction by postconditioning, possibly via other mechanism(s) of the ERK and Akt pathways." | 1.35 | Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol. ( Maruyama, Y; Oikawa, M; Watanabe, K; Yaoita, H, 2008) |
| "Carvedilol is an alpha-and beta-blocking agent with antioxidant properties." | 1.33 | In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart. ( Hegna, S; Johansen, OE; Mjøs, OD; Munch-Ellingsen, J; Starkopf, J; Ytrehus, K, 2006) |
| "Carvedilol pretreated patients had higher amount of serum UA (p<0." | 1.33 | Elevated serum uric acid reduce heart damage in patients undergoing opern-heart surgery. ( Blagojevć, D; Davidović, B; Kastratović, D; Mijalković, D; Nikolić, A; Spasić, M, 2006) |
| "Carvedilol was compared with two doses of propranolol, 1." | 1.31 | Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. ( Bernocchi, P; Boraso, A; Cargnoni, A; Ceconi, C; Curello, S; Ferrari, R; Parrinello, G, 2000) |
| "SB 211475 was administered either as 0." | 1.30 | SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits. ( Brunvand, H; Feuerstein, GZ; Liu, G; Ma, XL; Ruffolo, RR; Yue, TL, 1998) |
| "Treatment with carvedilol reduced IS more than did treatment with propranolol/doxazosin (p < 0." | 1.29 | Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms. ( Berge, RK; Brunvand, H; Grong, K; Kvitting, PM; Rynning, SE, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (38.46) | 18.2507 |
| 2000's | 14 (53.85) | 29.6817 |
| 2010's | 1 (3.85) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Aonuma, T | 1 |
| Moukette, B | 1 |
| Kawaguchi, S | 1 |
| Barupala, NP | 1 |
| Sepúlveda, MN | 1 |
| Corr, C | 1 |
| Tang, Y | 1 |
| Liangpunsakul, S | 1 |
| Payne, RM | 1 |
| Willis, MS | 1 |
| Kim, IM | 1 |
| Yeh, CH | 1 |
| Chen, TP | 1 |
| Wang, YC | 1 |
| Lin, YM | 1 |
| Fang, SW | 1 |
| Zhao, JL | 1 |
| Yang, YJ | 1 |
| Pei, WD | 1 |
| Sun, YH | 1 |
| Zhai, M | 1 |
| Liu, YX | 1 |
| Gao, RL | 1 |
| Oikawa, M | 2 |
| Yaoita, H | 2 |
| Watanabe, K | 2 |
| Maruyama, Y | 2 |
| Zeng, H | 1 |
| Liu, X | 1 |
| Zhao, H | 1 |
| Oliveira, PJ | 1 |
| Gonçalves, L | 1 |
| Monteiro, P | 2 |
| Providencia, LA | 2 |
| Moreno, AJ | 1 |
| Fan, SY | 1 |
| Ke, YN | 1 |
| Zeng, YJ | 1 |
| Wang, Y | 1 |
| Cheng, WL | 1 |
| Yang, JR | 1 |
| Ogawa, K | 1 |
| Maehara, K | 1 |
| Zhao, J | 1 |
| Yang, Y | 1 |
| you, S | 1 |
| Cui, C | 1 |
| Gao, R | 1 |
| Starkopf, J | 1 |
| Hegna, S | 1 |
| Johansen, OE | 1 |
| Munch-Ellingsen, J | 1 |
| Mjøs, OD | 1 |
| Ytrehus, K | 1 |
| Nikolić, A | 2 |
| Mijalković, D | 1 |
| Kastratović, D | 1 |
| Blagojevć, D | 1 |
| Davidović, B | 1 |
| Spasić, M | 1 |
| Carreira, RS | 1 |
| Gon Alves, LM | 1 |
| Jaggi, AS | 1 |
| Singh, M | 1 |
| Sharma, A | 1 |
| Singh, D | 1 |
| Singh, N | 1 |
| Ma, XL | 5 |
| Yue, TL | 5 |
| Lopez, BL | 1 |
| Barone, FC | 1 |
| Christopher, TA | 1 |
| Ruffolo, RR | 5 |
| Feuerstein, GZ | 4 |
| Brunvand, H | 3 |
| Kvitting, PM | 1 |
| Rynning, SE | 2 |
| Berge, RK | 2 |
| Grong, K | 2 |
| Kramer, JH | 1 |
| Weglicki, WB | 1 |
| Frłyland, L | 1 |
| Hexeberg, E | 1 |
| Wang, X | 1 |
| Romanic, AM | 1 |
| Liu, GL | 2 |
| Louden, C | 1 |
| Gu, JL | 2 |
| Kumar, S | 1 |
| Poste, G | 1 |
| Feuerstein, G | 1 |
| Cheng, HY | 1 |
| Hieble, JP | 1 |
| Arch, JR | 1 |
| Khandoudi, N | 1 |
| Percevault-Albadine, J | 1 |
| Bril, A | 1 |
| Liu, G | 1 |
| Cargnoni, A | 1 |
| Ceconi, C | 1 |
| Bernocchi, P | 1 |
| Boraso, A | 1 |
| Parrinello, G | 1 |
| Curello, S | 1 |
| Ferrari, R | 1 |
| Takusagawa, M | 1 |
| Komori, S | 1 |
| Matsumura, K | 1 |
| Osada, M | 1 |
| Kohno, I | 1 |
| Umetani, K | 1 |
| Ishihara, T | 1 |
| Sawanobori, T | 1 |
| Ijiri, H | 1 |
| Tamura, K | 1 |
| Habon, T | 1 |
| Szabados, E | 1 |
| Kesmarky, G | 1 |
| Halmosi, R | 1 |
| Past, T | 1 |
| Sumegi, B | 1 |
| Toth, K | 1 |
| Smith, EF | 1 |
| Griswold, DE | 1 |
| Hillegass, LM | 1 |
| Slivjak, MJ | 1 |
| Davis, PA | 1 |
| DiMartino, MJ | 1 |
2 reviews available for carvedilol and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Are the antioxidant properties of carvedilol important for the protection of cardiac mitochondria?
Topics: Adrenergic beta-Antagonists; Animals; Antioxidants; Carbazoles; Cardiomyopathies; Carvedilol; Humans | 2005 |
Carvedilol: just another Beta-blocker or a powerful cardioprotector?
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Antibiotics, Antineopl | 2006 |
24 other studies available for carvedilol and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Cardiomyocyte microRNA-150 confers cardiac protection and directly represses proapoptotic small proline-rich protein 1A.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carvedilol; Cornified Envelope Proline-Rich Protein | 2021 |
Carvedilol treatment after myocardial infarct decreases cardiomyocytic apoptosis in the peri-infarct zone during cardioplegia-induced cardiac arrest.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Biomarkers; Carbazoles; Carvedilol; Dose-Response R | 2013 |
Carvedilol reduces myocardial no-reflow by decreasing endothelin-1 via activation of the ATP-sensitive K+ channel.
Topics: Animals; Antihypertensive Agents; Carbazoles; Carvedilol; Disease Models, Animal; Endothelin-1; Glyb | 2008 |
Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Stenosis; Disease Models, Ani | 2008 |
Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Apoptosis; bcl-2-Associated X Pr | 2003 |
[Effects and the mechanism of carvedilol on gap junctional intercellular communication in rat myocardium].
Topics: Animals; Carbazoles; Carvedilol; Cell Communication; Connexin 43; Gap Junctions; Male; Myocardial Re | 2005 |
Attenuated cardioprotection by ischemic preconditioning in coronary stenosed heart and its restoration by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Coronary Stenosis; Drug Evaluation, Pr | 2006 |
Carvedilol preserves endothelial junctions and reduces myocardial no-reflow after acute myocardial infarction and reperfusion.
Topics: Adrenergic alpha-Antagonists; Animals; Blood Flow Velocity; Blotting, Western; Carbazoles; Carvedilo | 2007 |
In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart.
Topics: Adrenergic alpha-Antagonists; Animals; Carbazoles; Carvedilol; Diastole; Ischemic Preconditioning, M | 2006 |
Elevated serum uric acid reduce heart damage in patients undergoing opern-heart surgery.
Topics: Aged; Antioxidants; Carbazoles; Carvedilol; Coronary Artery Bypass; Creatine Kinase; Humans; Male; M | 2006 |
Cardioprotective effects of mast cell modulators in ischemia-reperfusion-induced injury in rats.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Creatine Kinase; Histamine H1 Antagoni | 2007 |
Carvedilol, a new beta adrenoreceptor blocker and free radical scavenger, attenuates myocardial ischemia-reperfusion injury in hypercholesterolemic rabbits.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Carbazoles; Carvedilol; Endothelium, Vascular; | 1996 |
Carvedilol protects against lethal reperfusion injury through antiadrenergic mechanisms.
Topics: Adrenergic Antagonists; Animals; Carbazoles; Carvedilol; Cats; Doxazosin; Free Radical Scavengers; G | 1996 |
A hydroxylated analog of the beta-adrenoceptor antagonist, carvedilol, affords exceptional antioxidant protection to postischemic rat hearts.
Topics: Adrenergic beta-Antagonists; Alcohols; Animals; Antioxidants; Carbazoles; Carvedilol; Dose-Response | 1996 |
Carvedilol improves function and reduces infarct size in the feline myocardium by protecting against lethal reperfusion injury.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Cats; Coronary Vessels; Hemodynamics; | 1996 |
Possible involvement of stress-activated protein kinase signaling pathway and Fas receptor expression in prevention of ischemia/reperfusion-induced cardiomyocyte apoptosis by carvedilol.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Carbazoles; Carvedilol; DNA Fragmentation; Down-Reg | 1998 |
Carvedilol inhibits activation of stress-activated protein kinase and reduces reperfusion injury in perfused rabbit heart.
Topics: Adrenergic beta-Antagonists; Animals; Calcium-Calmodulin-Dependent Protein Kinases; Carbazoles; Carv | 1998 |
Comparison of metoprolol and carvedilol pharmacology and cardioprotection in rabbit ischemia and reperfusion model.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antioxidants; Blood Pressure; Ca | 1998 |
Comparative effects of carvedilol and metoprolol on cardiac ischemia-reperfusion injury.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; L-La | 1998 |
SB 211475, a metabolite of carvedilol, reduces infarct size after myocardial ischemic and reperfusion injury in rabbits.
Topics: Adrenergic alpha-Antagonists; Animals; Antioxidants; Carbazoles; Carvedilol; Dose-Response Relations | 1998 |
Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Adrenergic beta-Antagonists; Analysis of Variance; An | 2000 |
The inhibitory effects of carvedilol against arrhythmias induced by coronary reperfusion in anesthetized rats.
Topics: Adrenergic beta-Antagonists; Anesthesia, General; Animals; Arrhythmias, Cardiac; Carbazoles; Carvedi | 2000 |
The effect of carvedilol on enhanced ADP-ribosylation and red blood cell membrane damage caused by free radicals.
Topics: Adenosine Diphosphate Ribose; ADP Ribose Transferases; Adrenergic Antagonists; Animals; Blood Viscos | 2001 |
Cardioprotective effects of the vasodilator/beta-adrenoceptor blocker, carvedilol, in two models of myocardial infarction in the rat.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Disease Models, Animal; Dose-Response | 1992 |